OSR Holdings (OSRH) said Thursday it signed an agreement allowing it to sell up to $80 million in stock to White Lion GBM Innovation Fund.
The capital will support OSR's global efforts to develop new therapies, including glioblastoma treatments, the company said.
The funding agreement gives OSR the option to sell shares gradually over time but does not obligate it to do so.
OSR's biotech portfolio includes Vaximm, a Swiss subsidiary developing an immunotherapy vaccine for glioblastoma.
Shares of the company were up more than 55% in recent Thursday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.